LCM
VRTX icon

LCM Capital Management’s Vertex Pharmaceuticals VRTX Stock Holding History

LCM Capital Management’s Portfolio VRTX Stock Details VRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$594K Buy
1,196
+38
+3% +$16.8K 0.26% 51
2026
Q1 		$517K Buy
1,158
+23
+2% +$10.7K 0.26% 50
2025
Q4 		$515K Sell
1,135
-10
-0.9% -$4.31K 0.25% 47
2025
Q3 		$448K Sell
1,145
-3
-0.3% -$1.25K 0.22% 53
2025
Q2 		$511K Buy
1,148
+4
+0.3% +$1.84K 0.27% 50
2025
Q1 		$555K Buy
1,144
+71
+7% +$33.1K 0.33% 47
2024
Q4 		$432K Buy
1,073
+19
+2% +$8.81K 0.24% 55
2024
Q3 		$490K Buy
1,054
+58
+6% +$27.9K 0.28% 51
2024
Q2 		$467K Buy
996
+56
+6% +$24.3K 0.29% 49
2024
Q1 		$393K Buy
940
+14
+2% +$5.92K 0.25% 55
2023
Q4 		$377K Buy
926
+16
+2% +$5.91K 0.27% 55
2023
Q3 		$316K Buy
910
+113
+14% +$39.5K 0.26% 57
2023
Q2 		$280K Buy
797
+39
+5% +$13.1K 0.23% 67
2023
Q1 		$239K Buy
+758
New +$227K 0.21% 74

Other funds holding VRTX

Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

LCM Capital Management's VRTX Position: Q2 2026 in Review

LCM Capital Management increased its Vertex Pharmaceuticals (VRTX) stake by 3.3% in Q2 2026, buying an estimated $16.8K and bringing the position to 1,196 shares worth $594K. The position accounts for 0.26% of the portfolio, ranked #51.

LCM Capital Management first reported a position in VRTX in Q1 2023 and has held it in 14 quarters since. 1,758 funds tracked by Wall St. Rank hold VRTX as of Q2 2026.

  • LCM Capital Management held 1,196 shares of Vertex Pharmaceuticals worth $594K as of Q2 2026.
  • LCM Capital Management bought 38 Vertex Pharmaceuticals shares in Q2 2026, an estimated $16.8K.
  • Vertex Pharmaceuticals made up 0.26% of LCM Capital Management's portfolio in Q2 2026, its #51 holding.
  • LCM Capital Management first reported a position in Vertex Pharmaceuticals in Q1 2023 and has held it in 14 quarters since.
  • 1,758 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q2 2026.

Based on LCM Capital Management's 13F filing for Q2 2026, filed 30 Jul 2026.